These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16801327)

  • 1. Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
    Serebruany VL
    Eur Heart J; 2006 Aug; 27(15):1886-7; author reply 1887-8. PubMed ID: 16801327
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
    Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
    J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel versus clopidogrel.
    Pasceri V; Patti G; Di Sciascio G
    N Engl J Med; 2008 Mar; 358(12):1298-9; author reply 1299-301. PubMed ID: 18357638
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Jernberg T; Payne CD; Winters KJ; Darstein C; Brandt JT; Jakubowski JA; Naganuma H; Siegbahn A; Wallentin L
    Eur Heart J; 2006 May; 27(10):1166-73. PubMed ID: 16621870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from prasugrel to clopidogrel: navigating in unknown waters.
    Angiolillo DJ; Rollini F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):166-8. PubMed ID: 23428008
    [No Abstract]   [Full Text] [Related]  

  • 8. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
    Bernlochner I; Mayer K; Morath T; Braun S; Schulz S; Schömig A; Koch W; Kastrati A; Sibbing D
    Platelets; 2013; 24(6):500-2. PubMed ID: 22916844
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
    Erlinge D; Ten Berg J; Foley D; Angiolillo DJ; Wagner H; Brown PB; Zhou C; Luo J; Jakubowski JA; Moser B; Small DS; Bergmeijer T; James S; Winters KJ
    J Am Coll Cardiol; 2012 Nov; 60(20):2032-40. PubMed ID: 23083774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring antiplatelet therapy--insanity or good sense?
    Laine M; Toesca R; Frere C; Paganelli F; Bonello L
    Circ J; 2013; 77(5):1150-1. PubMed ID: 23524446
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
    Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
    Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?
    Kristensen SD; Grove EL; Hvas AM
    Thromb Haemost; 2012 Aug; 108(2):203-5. PubMed ID: 22739804
    [No Abstract]   [Full Text] [Related]  

  • 15. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
    Bernlochner I; Morath T; Brown PB; Zhou C; Baker BA; Gupta N; Jakubowski JA; Winters KJ; Schömig A; Kastrati A; Sibbing D
    Platelets; 2013; 24(1):15-25. PubMed ID: 22372531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy.
    Felix-Getzik E; Sylvia LM
    Am J Health Syst Pharm; 2013 Mar; 70(6):511-3. PubMed ID: 23456404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
    Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a therapeutic window for antiplatelet therapy in the elderly.
    Gurbel PA; Ohman EM; Jeong YH; Tantry US
    Eur Heart J; 2012 May; 33(10):1187-9. PubMed ID: 22270540
    [No Abstract]   [Full Text] [Related]  

  • 19. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
    Goto S; Tomiya A
    Thromb Haemost; 2013 Feb; 109(2):177-8. PubMed ID: 23306954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.